Last updated: February 16, 2026
Product Overview
NDC 60505-3438 corresponds to Ranolazine Extended-Release Tablets, 500mg, marketed under the brand name Ranexa. Approved by the FDA in 2006, Ranexa is indicated for chronic angina management in adult patients. It is prescribed as part of long-term angina treatment to improve exercise capacity and reduce angina episodes.
Market Size and Dynamics
The ranolazine market is characterized by increasing demand driven by the growth in coronary artery disease (CAD) prevalence.
- Market Volume (2022): Estimated at approximately 1.2 million prescriptions in the U.S.
- Annual Sales (2022): Approximate revenue reached $1.2 billion.
- Market Growth Rate: Compound annual growth rate (CAGR) around 3-4% over the past five years, reflecting broader trends in cardiovascular disease management.
Competitive Landscape
Ranolazine faces competition from other angina treatments, primarily nitrates, beta-blockers, and calcium channel blockers. Its niche is as an add-on therapy or for patients intolerant to first-line agents.
- Key Competitors: Isosorbide dinitrate, beta-blockers, calcium channel blockers.
- Market Share: Ranexa holds an estimated 20% of the chronic angina market segment.
Price Trends and Projections
Current Pricing
- Average Wholesale Price (AWP) for a 30-day supply (30 x 500mg tablets): $300 - $350.
- Estimated Out-of-Pocket Cost: $50 - $100 with insurance, depending on pharmacy benefits.
Price Drivers
- Patent Status: Ranexa’s patent expired in 2025, opening the market to generic competition.
- Generics Introduction: Generic ranolazine launched in mid-2025, leading to significant price erosion.
- Market Penetration: Post-generic launch, prices dropped by approximately 60-70%.
Future Price Projections
- 2023-2024: Generic competition stabilizes prices around $30 - $50 per month.
- 2025-2026: Prices are expected to remain stable or decline slightly, assuming no major policy or supply chain disruptions.
- Long-term (2027 and beyond): Price levels could stabilize around $20 - $30 per month, depending on market dynamics and payer negotiations.
Regulatory and Policy Factors
- Recent policy shifts targeting drug price transparency may influence pricing strategies.
- Expanded insurance coverage for chronic cardiovascular therapies may affect pricing and uptake.
Key Considerations for Stakeholders
- Pharmaceutical Companies: The entry of generics has drastically reduced margins. Focus shifts to lifecycle management, such as extending patent life via formulations or combination therapies.
- Payers: Favor generics due to cost savings; incentives may promote switching from brand-name Ranexa.
- Healthcare Providers: Market prefers cost-effective therapies; prescribing patterns are influenced by formulary status and patient insurance.
Key Takeaways
- The initial market for NDC 60505-3438 was approximately $1.2 billion annually.
- Patent expiration in 2025 facilitated a shift toward generics, lowering prices by up to 70%.
- The current outlook suggests stabilization at $20-$50/month for generics, affecting revenues for brand-name formulations.
- Competitive pressure and policy changes will shape the future market trajectory.
FAQs
Q1: How does the patent expiration impact the drug's pricing?
Patent expiration allows generic manufacturers to enter the market, leading to increased competition and substantial price reductions.
Q2: What is the expected market size for Ranexa in the next five years?
Market share is expected to decline due to generics, with revenue potentially decreasing by 50% or more from peak levels.
Q3: Are there any emerging therapies threatening Ranexa’s market share?
Newer anti-anginal agents and device-based therapies could disrupt the market, but currently, Ranexa remains a key option for specific patient populations.
Q4: How do insurance policies influence Ranexa’s pricing?
Insurance coverage and formulary restrictions impact patient out-of-pocket costs and prescribing patterns, often favoring generics.
Q5: What strategies could pharmaceutical companies adopt post-patent?
They may develop new formulations, combination therapies, or pursue lifecycle extensions through orphan drug status or new indications.
References
- IQVIA. (2022). Pharmaceutical Market Data.
- FDA. (2006). Approval Letter for Ranolazine.
- EvaluatePharma. (2023). Top Pharmaceutical Products by Revenue.
- SSR Health. (2023). Pharmaceutical Price Trends.
- CDC. (2022). Prevalence of Coronary Heart Disease.
